Patrik Ringblom joined Galapagos as Head of Strategy & US Lead in October 2023. Patrik will lead the further establishment and expansion of Galapagos’ presence in the US, attracting top talent and increasing value creation in collaboration with strategic partners.
Patrik brings a wealth of experience having spent most of his career with Johnson & Johnson (J&J). Starting as a sales representative in Sweden, he progressed to global leadership roles at J&J.
In 2012, Patrik moved to the US and took on the role of VP Global Strategy Organization Oncology. During his 10 years in this role, he was part of the dedicated team that launched 10 transformational oncology medicines globally, several of which reached blockbuster status. In 2022, Patrik was appointed Vice President Rare Disease Novel Therapeutics & Alliance, with primary responsibility for driving external innovation of early and late-stage assets.
Patrik holds MBA from the Gothenburg School of Economics. He has a clear mission to fight cancer and improve patients’ quality of life, which has resulted in several life-saving medicines.